Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced intensity double umbilical cord blood transplantation in hematologic malignancies
NCT01408563Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2011
- Primary completion
- Jun 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of hematopoietic progenitor cells, cord blood in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), sponsored by Massachusetts General Hospital. Started Dec 2011; status: completed.
02
Drugs
hematopoietic progenitor cells, cord blood
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)multiple myeloma (MM)chronic lymphocytic leukemia (CLL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01408563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01408563.